Skip to main content

Table 3 Associations between TACE-Iodine 125 treatment and recurrence in patients with early-intermediate HCC before PSM

From: Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma

Characteristics HR (95%CI) P value Adjusted HR (95%CI) P value
Overall
 TACE-RFA Reference   Reference  
 TACE-Iodine 125 1.252 (0.805,1.950) 0.319 1.020 (0.645,1.611) 0.934
Child-Pugh A
 TACE-RFA Reference   Reference  
 TACE-Iodine 125 1.270 (0.749,2.154) 0.374 0.976 (0.566,1.685) 0.932
Child-Pugh B
 TACE-RFA Reference   Reference  
 TACE-Iodine 125 1.416 (0.598,3.354) 0.429 1.539 (0.560,4.232) 0.403
BCLC A
 TACE-RFA Reference   Reference  
 TACE-Iodine 125 0.816 (0.352,1.893) 0.636 0.601 (0.234,1.547) 0.291
BCLC B
 TACE-RFA Reference   Reference  
 TACE-Iodine 1.253 (0.724,2.169) 0.421 1.252 (0.722,2.171) 0.423
  1. Abbreviations: TACE Transarterial chemoembolization; RFA Radiofrequency ablation; BCLC Barcelona Clinic Liver Cancer